Kelly Services, Inc. (KELYA) At $30.24 Forms Top; AGILE THERAPEUTICS (AGRX) Sentiment Is 1.71

Kelly Services, Inc. (NASDAQ:KELYA) Logo

AGILE THERAPEUTICS INC (AGRX) investors sentiment increased to 1.71 in 2017 Q4. It’s up 0.36, from 1.35 in 2017Q3. The ratio has improved, as 29 hedge funds increased and opened new positions, while 17 sold and reduced their stakes in AGILE THERAPEUTICS INC. The hedge funds in our database now possess: 22.48 million shares, down from 23.16 million shares in 2017Q3. Also, the number of hedge funds holding AGILE THERAPEUTICS INC in top ten positions was flat from 4 to 4 for the same number . Sold All: 11 Reduced: 6 Increased: 16 New Position: 13.

Kelly Services, Inc. (KELYA) formed multiple top with $32.05 target or 6.00% above today’s $30.24 share price. Kelly Services, Inc. (KELYA) has $1.16B valuation. The stock increased 0.93% or $0.28 during the last trading session, reaching $30.24. About 125,997 shares traded. Kelly Services, Inc. (NASDAQ:KELYA) has risen 35.18% since April 14, 2017 and is uptrending. It has outperformed by 23.63% the S&P500.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $101.03 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on May, 14. They expect $-0.28 earnings per share, down 7.69% or $0.02 from last year’s $-0.26 per share. After $-0.18 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 55.56% negative EPS growth.

Proquest Associates Iv Llc holds 18.09% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.82 million shares or 5.95% of their US portfolio. Moreover, Aisling Capital Llc has 0.69% invested in the company for 1.30 million shares. The Sweden-based Investor Ab has invested 0.62% in the stock. Perceptive Advisors Llc, a New York-based fund reported 3.38 million shares.

The stock increased 1.03% or $0.03 during the last trading session, reaching $2.95. About 64,009 shares traded. Agile Therapeutics, Inc. (AGRX) has declined 11.00% since April 14, 2017 and is downtrending. It has underperformed by 22.55% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart